DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies ...
What: Shares in Aerie Pharmaceuticals jumped by nearly 50% earlier today after the company reported that the FDA is allowing it to change a primary endpoint on a key phase 3 trial evaluating its ...
Alcon AG said on Tuesday it would acquire Aerie Pharmaceuticals in a deal valued at about $753 million, as the Swiss eye-care company looks to bolster its pipeline of opthalmic treatments. Alcon has ...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback